Cell-based protein vaccines for influenza
- PMID:15732526
Cell-based protein vaccines for influenza
Abstract
An overview of influenza vaccines in development is provided, with an emphasis on new cell-based protein vaccine candidates. The current licensed vaccine is a cost-effective means to reduce the impact of influenza with a known mechanism of action. Most vaccine companies are focusing on the production of whole influenza viruses in various cell lines to replace egg-based manufacturing technology. Only a limited number of targets have been identified for the development of cell-based protein influenza vaccines. They include hemagglutinin, neuraminidase, M2 and nucleocapsid protein. These protein-based vaccine candidates are discussed, along with their progress in clinical development and the advantages and disadvantages of each vaccine approach.
Similar articles
- Progress on baculovirus-derived influenza vaccines.Cox MM.Cox MM.Curr Opin Mol Ther. 2008 Feb;10(1):56-61.Curr Opin Mol Ther. 2008.PMID:18228182Review.
- Influenza virus-like particle vaccines.Haynes JR.Haynes JR.Expert Rev Vaccines. 2009 Apr;8(4):435-45. doi: 10.1586/erv.09.8.Expert Rev Vaccines. 2009.PMID:19348559Review.
- Changing perspective on immunization against influenza.Johansson BE, Brett IC.Johansson BE, et al.Vaccine. 2007 Apr 20;25(16):3062-5. doi: 10.1016/j.vaccine.2007.01.030. Epub 2007 Jan 19.Vaccine. 2007.PMID:17276554Review.
- A one-size-fits-all flu vaccine?Kaiser J.Kaiser J.Science. 2006 Apr 21;312(5772):380-2. doi: 10.1126/science.312.5772.380.Science. 2006.PMID:16627732No abstract available.
- [Universal influenza vaccine still far in the future].Rimmelzwaan GF, Osterhaus AD.Rimmelzwaan GF, et al.Ned Tijdschr Geneeskd. 1999 Nov 13;143(46):2305-7.Ned Tijdschr Geneeskd. 1999.PMID:10589217Review.Dutch.
Cited by
- Developments of subunit and VLP vaccines against influenza A virus.Deng MP, Hu ZH, Wang HL, Deng F.Deng MP, et al.Virol Sin. 2012 Jun;27(3):145-53. doi: 10.1007/s12250-012-3241-1. Epub 2012 Jun 9.Virol Sin. 2012.PMID:22684468Free PMC article.Review.
- Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin.Song L, Zhang Y, Yun NE, Poussard AL, Smith JN, Smith JK, Borisevich V, Linde JJ, Zacks MA, Li H, Kavita U, Reiserova L, Liu X, Dumuren K, Balasubramanian B, Weaver B, Parent J, Umlauf S, Liu G, Huleatt J, Tussey L, Paessler S.Song L, et al.Vaccine. 2009 Sep 25;27(42):5875-84. doi: 10.1016/j.vaccine.2009.07.060. Epub 2009 Aug 3.Vaccine. 2009.PMID:19654064Free PMC article.
- Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.Kendirgi F, Yun NE, Linde NS, Zacks MA, Smith JN, Smith JK, McMicken H, Chen Y, Paessler S.Kendirgi F, et al.Hum Vaccin. 2008 Nov-Dec;4(6):410-9. doi: 10.4161/hv.4.6.6177. Epub 2008 Nov 21.Hum Vaccin. 2008.PMID:18443425Free PMC article.
- The application of virus-like particles as vaccines and biological vehicles.Yan D, Wei YQ, Guo HC, Sun SQ.Yan D, et al.Appl Microbiol Biotechnol. 2015 Dec;99(24):10415-32. doi: 10.1007/s00253-015-7000-8. Epub 2015 Oct 10.Appl Microbiol Biotechnol. 2015.PMID:26454868Free PMC article.Review.
- Evaluation of the Virus Counter® for rapid baculovirus quantitation.Ferris MM, Stepp PC, Ranno KA, Mahmoud W, Ibbitson E, Jarvis J, Cox MM, Christensen K, Votaw H, Edwards DP, Rowlen KL.Ferris MM, et al.J Virol Methods. 2011 Jan;171(1):111-6. doi: 10.1016/j.jviromet.2010.10.010. Epub 2010 Oct 21.J Virol Methods. 2011.PMID:20970458Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical